Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 0.67 |
| ▸ | CDK2 | P24941 | 20/20 | 0.67 |
| ▸ | CDK4 | P11802 | 5/20 | 0.67 |
| ▸ | CCND3 | P30281 | 5/20 | 0.67 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.67 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.58 |
| ▸ | PLK1 | P53350 | 12/20 | 0.58 |
| ▸ | AURKA | O14965 | 11/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.55 |
| ▸ | PLK2 | Q9NYY3 | 6/20 | 0.55 |
| ▸ | TTK | P33981 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940510 | 0.88 | CDK2 (0.60) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL9940794 | 0.87 | CCNA2 (0.69) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL10215996 | 0.83 | CDK2 (0.70) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL9940837 | 0.82 | CCNA2 (0.60) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL9940400 | 0.82 | CCNA2 (0.64) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL10218678 | 0.81 | CCNA2 (0.59) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL9940553 | 0.78 | CDK2 (0.69) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL9940913 | 0.78 | CCNA2 (0.65) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL9940866 | 0.78 | CCNA2 (0.61) | CCNA2CDK2CDK4CCND3CDK6 | |
| SCHEMBL9940668 | 0.78 | CCNA2 (0.65) | CCNA2CDK2CDK4CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2614065-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-07-17 | — | — | EP | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | CCNA2 1765/4885CDK2 113/4885CDK4 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.